Credit Suisse Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $82.17 -9.9%
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Credit Suisse upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Neutral to Outperform with a price target of $73.00.
For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $61.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $85 at Scotiabank
- JPMorgan Upgrades Dow Inc. (DOW) to Overweight
- Goldman Sachs Upgrades Akzo Nobel NV (AKZA:NA) (AKZOY) to Neutral
Create E-mail Alert Related Categories
UpgradesRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
